drugset / Trial / NCT06880393
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma
Timeline
- Start
- 2025-03-18
- Primary completion
- 2027-03
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-BCMA CAR-T | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | anti-BCMA CAR-T | Cell therapy | 4e+06 cells/kg | Intravenous |